@ARTICLE{
author={Trukhin Dmytro,Poddubskaya Elena,Andric Zoran G,Bondarenko Igor N,Shevnia Serhii,Zaric Bojan,Bellala Ravishankar,Charoentum Chaiyut,Perez Luis,Bullo Felicitas,Garcia Fernanda},
year={2021},
title={Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={39},
number={15},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Syrigos Konstantinos,Abert Istvan,Andric Zoran G,Bondarenko Igor N,Dvorkin Mikhail,Galic Kristina,Galiulin Rinat,Kuchava Vladimer,Sriuranpong Virote,Trukhin Dmytro,Zhavrid Edvard,Fu Dongyue,Kassalow Laurent M,Jones Stephanie,Bashir Zahid},
year={2021},
title={Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)},
journal={BIODRUGS},
volume={35},
number={4},
pages={417-428},
document_type={Article},
} 

@ARTICLE{
author={Trukhin Dmytro,...,Andric Zoran G,...,(broj koautora 19)},
year={2021},
title={Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)},
journal={BIODRUGS},
volume={35},
number={4},
pages={429-444},
document_type={Article},
} 

@ARTICLE{
author={Millan Susana,Trukhin Dmytro,Kolesnik Oleksii,Poddubskaya Elena,Andric Zoran G,Bondarenko Igor N,Shevnia Serhii,Bullo Felicitas,Sarnago Cristina},
year={2020},
title={Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={38},
number={15},
pages={-},
document_type={Meeting Abstract},
}